Enlivex Therapeutics Ltd.
- ENLV
- NASDAQ
- Biotechnology
- Immunotherapy
- Cell Therapy
- Macrophage Reprogramming
$0.21
Today +1.17%Quote Oct 19, 2026, 08:00 PM UTC
−71.81%over the last month
Max drawdown −74.6%From 1-month high −74.6%3 months −95.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
34
Market value
$49.2M
Quote Oct 19
Analyst target
$15.00
+7132.4% from here
Floor
$0.18
15.5% below price
Resistance
$0.30
45.9% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ENLVPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free